1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
BD furnished recast historical financials, with its former Biosciences and Diagnostic Solutions business shown as discontinued operations following its February 9, 2026 combination with Waters Corporation. For the quarter ended December 31, 2025, revenue rose to $4,486 million from $4,333 million, and GAAP diluted EPS was $1.34 versus $1.04, but adjusted diluted EPS from continuing operations fell to $2.50 from $2.78.
Revenue for the three months ended December 31, 2025 was $4,486 million, up from $4,333 million a year earlier.
GAAP diluted EPS was $1.34, compared with $1.04; diluted EPS from continuing operations was $1.09, compared with $0.50.
Adjusted diluted EPS from continuing operations was $2.50, down from $2.78; adjusted operating income was $978 million versus $1,005 million.
Roivant said its Immunovant unit's two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint, and it started a new Phase 2b/3 trial of brepocitinib in lichen planopilaris at Priovant. The filing also gave preliminary cash and marketable securities of about $4.3 billion as of March 31, 2026, and buybacks of about $109.7 million in the quarter, while the fiscal year audit is still ongoing.
Immunovant's two Phase 3 batoclimab studies in thyroid eye disease each failed to meet the primary endpoint of at least 2mm proptosis responder rate at Week 24; no new safety signals were identified.
Priovant began a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first subjects enrolled in March 2026.
Preliminary cash, cash equivalents and marketable securities were about $4.3 billion as of March 31, 2026.
Roivant repurchased 3,956,362 common shares for about $109.7 million (excluding fees and commission) in the three months ended March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.